ENDPOINTS

Stoke CEO Ed Kaye to depart shortly after inking Biogen pact and before its first Phase 3 trial

In a surprise move, the longtime CEO of Stoke Therapeutics is leaving the company, weeks before the Phase 3 trial of its lead drug is slated to start. The biotech

Mar 18, 2025 - 15:38
 0
Stoke CEO Ed Kaye to depart shortly after inking Biogen pact and before its first Phase 3 trial
In a surprise move, the longtime CEO of Stoke Therapeutics is leaving the company, weeks before the Phase 3 trial of its lead drug is slated to start. The biotech
Read More

Tags:

Previous Article

Plastic-degrading enzymes found in landfills

Next Article

An experiment in mass education using satellite TV

Related Posts

Eli Lilly-backed Maxion Therapeutics raises $72M Series A to advance its antibody approach

Eli Lilly-backed Maxion Therapeutics raises $72M Series...

Mar 17, 2025  0

Indian drugmakers join forces to boost national biomanufacturing sector  

Indian drugmakers join forces to boost national biomanu...

Feb 25, 2025  0

J&J, Protagonist outline first IBD win for potential immunological blockbuster

J&J, Protagonist outline first IBD win for potential im...

Mar 10, 2025  0